TY - JOUR AB - Resibufogenin (RBG) is an active ingredient of toad venom that also has antitumor potential. The present study aimed to investigate the role of RBG in multiple myeloma (MM) and the underlying action mechanism involving the PI3K/Akt signaling pathway. A human MM cell line, RPMI8226, was treated with RBG and/or insulin‑like growth factor 1 (IGF‑1; an activator of the PI3K/AKT signaling pathway). Cell viability and apoptosis were detected using Cell Counting Kit‑8 and flow cytometry, respectively. Cell migration and invasion were detected using a Transwell assay. In addition, the epithelial‑mesenchymal transition (EMT)‑associated proteins (E‑cadherin, N‑cadherin and Vimentin) and the PI3K/AKT pathway‑associated proteins [AKT, phosphorylated (p)‑AKT, PI3K and p‑PI3K] were measured using western blotting. RBG inhibited the viability, migration and invasion, and promoted the apoptosis of RPMI8226 cells in a dose‑dependent manner. RBG at concentrations of 4 and 8 µM upregulated E‑cadherin, and downregulated N‑cadherin and Vimentin in RPMI8226 cells. RBG also decreased the protein expression of p‑AKT and p‑PI3K in a dose‑dependent manner. In addition, the intervention of IGF‑1 weakened the inhibitory effects of RBG on the malignant characteristics of MM cells. RBG‑induced inhibition of EMT and the PI3K/AKT pathway were also weakened by IGF‑1 treatment. In conclusion, RBG inhibited viability, migration, invasion and EMT, and promoted the apoptosis of MM cells by blocking the PI3K/AKT signaling pathway. AD - Department of Hematology, The First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China The First Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China The First Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China AU - Zhou,Yan AU - Hong,Zirui AU - Jin,Keting AU - Lin,Chenjun AU - Xiang,Jingjing AU - Ge,Hangping AU - Zheng,Zhiyin AU - Shen,Jianping AU - Deng,Shu DA - 2022/07/01 DO - 10.3892/etm.2022.11368 IS - 1 JO - Exp Ther Med KW - resibufogenin multiple myeloma malignant characteristics PI3K/AKT signaling pathway antitumor PY - 2022 SN - 1792-0981 1792-1015 SP - 441 ST - Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway T2 - Experimental and Therapeutic Medicine TI - Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway UR - https://doi.org/10.3892/etm.2022.11368 VL - 24 ER -